Becton, Dickinson and Company (NYSE:BDX) Shares Sold by Wedmont Private Capital

Wedmont Private Capital trimmed its stake in shares of Becton, Dickinson and Company (NYSE:BDXGet Rating) by 44.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 884 shares of the medical instruments supplier’s stock after selling 714 shares during the period. Wedmont Private Capital’s holdings in Becton, Dickinson and were worth $218,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Sound Income Strategies LLC increased its stake in shares of Becton, Dickinson and by 71.1% during the 2nd quarter. Sound Income Strategies LLC now owns 296 shares of the medical instruments supplier’s stock worth $73,000 after purchasing an additional 123 shares in the last quarter. State of Alaska Department of Revenue increased its stake in shares of Becton, Dickinson and by 0.7% during the 2nd quarter. State of Alaska Department of Revenue now owns 40,940 shares of the medical instruments supplier’s stock worth $10,092,000 after purchasing an additional 265 shares in the last quarter. Laurel Wealth Advisors Inc. purchased a new position in shares of Becton, Dickinson and during the 4th quarter worth approximately $208,000. Calamos Wealth Management LLC purchased a new position in shares of Becton, Dickinson and during the 1st quarter worth approximately $256,000. Finally, Advisor Resource Council purchased a new position in shares of Becton, Dickinson and during the 4th quarter worth approximately $236,000. 86.74% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. StockNews.com raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Saturday, September 10th. Citigroup cut shares of Becton, Dickinson and from a “neutral” rating to a “sell” rating and lowered their target price for the stock from $265.00 to $235.00 in a research note on Monday, July 11th. The Goldman Sachs Group lifted their target price on shares of Becton, Dickinson and from $278.00 to $319.00 and gave the stock a “buy” rating in a research note on Tuesday, August 16th. Morgan Stanley lowered their target price on shares of Becton, Dickinson and from $282.00 to $272.00 and set an “overweight” rating for the company in a research note on Friday, July 15th. Finally, Wells Fargo & Company raised shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and set a $275.00 target price for the company in a research note on Friday, June 24th. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Becton, Dickinson and has a consensus rating of “Hold” and an average target price of $277.63.

Insider Activity

In related news, EVP David Hickey sold 475 shares of Becton, Dickinson and stock in a transaction on Monday, August 15th. The shares were sold at an average price of $265.00, for a total transaction of $125,875.00. Following the transaction, the executive vice president now owns 3,331 shares in the company, valued at approximately $882,715. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP David Hickey sold 475 shares of Becton, Dickinson and stock in a transaction on Monday, August 15th. The shares were sold at an average price of $265.00, for a total transaction of $125,875.00. Following the transaction, the executive vice president now owns 3,331 shares in the company, valued at approximately $882,715. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Samrat S. Khichi sold 9,185 shares of the business’s stock in a transaction on Tuesday, August 9th. The stock was sold at an average price of $260.44, for a total transaction of $2,392,141.40. Following the completion of the transaction, the executive vice president now owns 5,928 shares in the company, valued at approximately $1,543,888.32. The disclosure for this sale can be found here. Insiders sold 19,160 shares of company stock valued at $5,036,751 in the last ninety days. Company insiders own 0.50% of the company’s stock.

Becton, Dickinson and Stock Down 2.8 %

Shares of NYSE BDX opened at $244.11 on Wednesday. Becton, Dickinson and Company has a 52-week low of $231.46 and a 52-week high of $280.62. The firm has a fifty day moving average of $252.11 and a 200-day moving average of $254.39. The stock has a market capitalization of $69.62 billion, a PE ratio of 42.09, a P/E/G ratio of 3.33 and a beta of 0.57. The company has a quick ratio of 0.90, a current ratio of 1.35 and a debt-to-equity ratio of 0.58.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings data on Thursday, August 4th. The medical instruments supplier reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Becton, Dickinson and had a net margin of 8.88% and a return on equity of 14.55%. The company had revenue of $4.64 billion during the quarter, compared to analysts’ expectations of $4.47 billion. During the same period in the previous year, the company earned $2.74 EPS. The business’s quarterly revenue was down 5.1% compared to the same quarter last year. On average, analysts anticipate that Becton, Dickinson and Company will post 11.31 EPS for the current year.

Becton, Dickinson and Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, September 30th. Stockholders of record on Friday, September 9th will be paid a dividend of $0.87 per share. The ex-dividend date of this dividend is Thursday, September 8th. This represents a $3.48 annualized dividend and a dividend yield of 1.43%. Becton, Dickinson and’s dividend payout ratio is presently 60.00%.

About Becton, Dickinson and

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Further Reading

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.